Continuity Biosciences, LLC, a new bioscience company dedicated to developing and commercializing cutting-edge technologies for cell reprogramming, immune modulation, and drug delivery, has officially launched.
 
The company seeks to bridge biopharmaceutical and medical technologies, establishing a new standard for patient-focused treatments for chronic and complex diseases.
 
Founded by a team of experienced scientists and industry leaders, Continuity Biosciences aims to enhance emerging therapies, such as cell therapy, by fully leveraging delivery technology.
 
The team includes:
 

• Bob Whitehead (Executive Chairman), a veteran in the bioscience field known for successful strategic exits and initiatives;
• Ramakrishna Venugopalan, PhD (Co-Founder & CEO), a former senior executive at AbbVie with expertise in drug delivery for products like Skyrizi and Vyalev;
• Alessandro Grattoni, PhD (Chief Scientific Advisor), Chair and Professor of the Department of Nanomedicine at Houston Methodist Hospital and a leader in advanced drug delivery.

 
“We are thrilled to have licensed several technology platforms from Houston Methodist Hospital and to introduce Continuity Biosciences to the biotechnology and investment communities,” said Ramakrishna Venugopalan, Co-Founder & CEO. “There is immense potential at the intersection of biopharmaceuticals and medical technologies, especially in creating combination products that enhance novel therapies. We plan to expand our technology portfolio to provide our partners with diverse strategies for delivering their treatments.”
 
Dr. Grattoni’s research and Continuity’s licensed technologies focus on implantable nanofluidic systems for cell reprogramming, molecular sieving, immune modulation, and long-term therapeutic release. Well-funded by organizations like the National Institute of Health and pharmaceutical partners, these platforms have vast potential for chronic condition treatment, including cancer, autoimmune, metabolic, and infectious diseases. They also enable long-acting drug delivery and in vivo cell reprogramming for advanced cell and gene therapies.